NASDAQ:BABY', 'Natus Medical Incorporated', '');

Natus Medical Incorporated (NASDAQ:BABY) Has Decline in Shorts

December 8, 2017 - By Kurt Siggers

 Natus Medical Incorporated (NASDAQ:BABY) Has Decline in Shorts

Investors sentiment increased to 1.17 in Q2 2017. Its up 0.19, from 0.98 in 2017Q1. It improved, as 25 investors sold Natus Medical Incorporated shares while 61 reduced holdings. 32 funds opened positions while 69 raised stakes. 30.57 million shares or 0.67% more from 30.36 million shares in 2017Q1 were reported.
Moreover, Sei has 0% invested in Natus Medical Incorporated (NASDAQ:BABY). Corsair Capital Lp reported 57,293 shares. Alps Advisors reported 12,906 shares. Sio Cap Mngmt Llc reported 68,095 shares stake. First Mercantile has 0.09% invested in Natus Medical Incorporated (NASDAQ:BABY). Price T Rowe Assocs Md holds 0% in Natus Medical Incorporated (NASDAQ:BABY) or 460,493 shares. Petrus Tru Lta has invested 0.1% in Natus Medical Incorporated (NASDAQ:BABY). 146,820 are owned by Bank & Trust Of America Corporation De. Legal & General Gp Public Ltd Co has 63,755 shares for 0% of their portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% in Natus Medical Incorporated (NASDAQ:BABY) or 855 shares. Advisory Network Ltd Company invested in 0% or 448 shares. Strs Ohio holds 0.02% or 105,000 shares. State Street invested in 0% or 856,576 shares. Etrade Capital Mgmt Limited Com owns 44,305 shares. Guggenheim Ltd Liability owns 0% invested in Natus Medical Incorporated (NASDAQ:BABY) for 9,119 shares.

Since June 15, 2017, it had 1 buying transaction, and 0 sales for $135,900 activity.

The stock of Natus Medical Incorporated (NASDAQ:BABY) registered a decrease of 6.31% in short interest. BABY’s total short interest was 3.36M shares in December as published by FINRA. Its down 6.31% from 3.59M shares, reported previously. With 419,800 shares average volume, it will take short sellers 8 days to cover their BABY’s short positions. The short interest to Natus Medical Incorporated’s float is 10.79%.

The stock decreased 0.92% or $0.35 during the last trading session, reaching $37.9. About 330,148 shares traded. Natus Medical Incorporated (NASDAQ:BABY) has risen 4.38% since December 8, 2016 and is uptrending. It has underperformed by 12.32% the S&P500.

Natus Medical Incorporated provides newborn care and neurology healthcare services and products worldwide. The company has market cap of $1.16 billion. It offers services and products used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders. It currently has negative earnings. The companyÂ’s product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories.

Natus Medical Incorporated (NASDAQ:BABY) Ratings Coverage

Among 4 analysts covering Natus Medical (NASDAQ:BABY), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Natus Medical has $55 highest and $39 lowest target. $49.67’s average target is 31.06% above currents $37.9 stock price. Natus Medical had 9 analyst reports since July 23, 2015 according to SRatingsIntel. The rating was maintained by Roth Capital on Tuesday, April 5 with “Buy”. As per Tuesday, January 12, the company rating was maintained by TH Capital. The firm has “Buy” rating given on Friday, June 23 by Roth Capital. TH Capital maintained Natus Medical Incorporated (NASDAQ:BABY) rating on Thursday, October 22. TH Capital has “Buy” rating and $53 target. The stock of Natus Medical Incorporated (NASDAQ:BABY) has “Buy” rating given on Monday, September 11 by Roth Capital. TH Capital maintained Natus Medical Incorporated (NASDAQ:BABY) rating on Thursday, July 23. TH Capital has “Buy” rating and $51 target. The rating was upgraded by Raymond James on Tuesday, September 13 to “Outperform”. As per Thursday, February 2, the company rating was downgraded by Raymond James. Benchmark initiated Natus Medical Incorporated (NASDAQ:BABY) on Tuesday, October 4 with “Buy” rating.

More important recent Natus Medical Incorporated (NASDAQ:BABY) news were published by: which released: “Natus Medical’s (BABY) CEO James Hawkins on Q2 2017 Results – Earnings Call …” on July 26, 2017, also published article titled: “Natus Medical Inc. Fell 11% in April. Here’s Why.”, published: “Natus Medical Inc: This BABY Has Some Growing Pains” on April 27, 2017. More interesting news about Natus Medical Incorporated (NASDAQ:BABY) was released by: and their article: “ highlights: Natus Medical, GoPro, Enviva Partners and Bruker” with publication date: November 15, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.